By Budi Oetomo Narendra 
Seoul, South Korea – Researchers at the Institute for Basic Science (IBS) have unveiled a potentially transformative therapeutic strategy for autism spectrum disorder (ASD), focusing on restoring the critical function of brain receptors vital for neural communication. The pioneering study, spearheaded by Director Eunjoon Kim of the IBS Center for Synaptic Brain Dysfunctions, zeroes in on a specific glycine transporter, identified as Slc6a20a/SLC6A20, proposing a novel pathway to address a core neurological deficit linked to ASD and other neurodevelopmental conditions.
The core of this significant discovery lies in the team’s finding that modulating the activity of the Slc6a20a/SLC6A20 transporter can effectively restore the proper function of NMDA receptors (NMDARs). These receptors are paramount to synaptic plasticity, serving as crucial gatekeepers for communication between brain cells and underpinning fundamental cognitive processes such as learning, memory formation, and higher-order thought. Dysfunction of NMDARs has long been implicated in a spectrum of severe neurological and psychiatric conditions, including ASD, schizophrenia, intellectual disability, and NMDAR encephalitis, making their restoration a long-sought goal in neuroscience.
The Persistent Challenge of NMDA Receptor Dysfunction
For decades, the scientific community has grappled with the challenge of enhancing NMDAR function to alleviate the symptoms of associated disorders. Despite extensive research and numerous clinical trials, previous therapeutic approaches have largely yielded inconsistent results, often accompanied by significant limitations and unwanted side effects. This historical context underscores the pressing need for more precise and targeted interventions, a need that the IBS team’s work directly addresses.
Autism spectrum disorder, a complex neurodevelopmental condition characterized by persistent challenges in social communication and interaction, and by restricted, repetitive patterns of behavior, interests, or activities, affects approximately 1 in 36 children in the United States, according to the Centers for Disease Control and Prevention (CDC) in 2023. Globally, its prevalence continues to be a major public health concern, imposing substantial personal, familial, and societal burdens. The economic impact of ASD, including healthcare, educational, and lost productivity costs, is estimated to be hundreds of billions of dollars annually, highlighting the urgent demand for effective treatments that can improve quality of life and functional outcomes.
The intricate mechanism of NMDAR activation requires the simultaneous presence of two key neurotransmitters: glutamate and a co-agonist, typically glycine or D-serine. Prior therapeutic strategies, aiming to boost NMDAR activity, often focused on increasing glycine levels by blocking another transporter known as GlyT1. While seemingly logical, this approach proved problematic. GlyT1 is widely distributed throughout the brain, including critical regions of the brainstem that regulate fundamental autonomic functions such as breathing and movement. Consequently, therapies targeting GlyT1 frequently led to dose-limiting side effects and offered only modest clinical benefits, dampening enthusiasm for this broad-spectrum strategy.
A More Targeted Approach: Precision in Brain Signaling
The IBS researchers, recognizing the limitations of previous broad-stroke interventions, chose a distinctly different and more targeted approach. Their focus on Slc6a20a/SLC6A20 is predicated on its highly restricted expression profile within the brain. Unlike GlyT1, Slc6a20a is predominantly found in specific brain regions crucial for cognition, notably the cerebral cortex and the hippocampus. This selective localization offers a profound advantage: by modulating Slc6a20a, it becomes theoretically possible to enhance NMDAR activity specifically where it is most needed for cognitive function, while minimizing undesirable effects on other essential brain functions regulated by more ubiquitously expressed transporters. This precision represents a significant paradigm shift in the pursuit of effective treatments for NMDAR hypofunction.
The Research Trajectory: From Mouse Models to Human Organoids
The journey to this discovery involved a meticulous, multi-stage research process, beginning with the identification of Slc6a20a as a promising target and progressing through rigorous experimental validation.
Initial Validation in Mouse Models of Autism:
To test their hypothesis, the research team utilized antisense oligonucleotides (ASOs) to selectively reduce the expression of Slc6a20a. ASOs are short synthetic nucleic acid sequences designed to bind to specific messenger RNA (mRNA) molecules, preventing the synthesis of target proteins and effectively silencing the gene. This sophisticated genetic tool allowed for precise manipulation of Slc6a20a levels.
The ASO treatment was administered to mouse models carrying mutations in SHANK2 and SHANK3, two genes recognized as major risk factors for autism and also implicated in other severe neurodevelopmental disorders, including Phelan-McDermid syndrome. These genetic models accurately recapitulate many of the neurological and behavioral deficits observed in human ASD.
The results from these preclinical trials were highly encouraging. Treatment with the Slc6a20a ASO successfully restored NMDAR activity across several autism-related mouse models. Crucially, this neurological restoration translated into significant behavioral improvements. The treated mice exhibited marked amelioration of difficulties associated with social interaction, social communication, and repetitive behaviors—the hallmark symptoms of ASD.
A particularly noteworthy finding from this phase of the study was the efficacy of the treatment in adult mice. This observation challenges the long-held belief that neurodevelopmental disorders, particularly those with a genetic basis, are only treatable during critical windows of early brain development. The fact that NMDAR dysfunction could still be effectively addressed after major stages of brain development are complete opens up exciting possibilities for therapeutic intervention in older children, adolescents, and even adults with ASD, offering hope beyond early diagnosis.
To understand the underlying mechanisms of these improvements, the researchers conducted extensive large-scale phospho-proteomic analyses. This advanced technique allowed them to examine changes in protein phosphorylation—a key post-translational modification that regulates protein function—across the brain. Their findings revealed that the ASO therapy caused relatively minor alterations in the overall abundance of proteins. Instead, the treatment precisely corrected abnormal phosphorylation patterns in proteins that are critical regulators of synaptic signaling and NMDAR function. This suggests that the therapeutic approach does not merely increase or decrease the quantity of specific proteins but rather restores the correct functional state of existing proteins, a more subtle yet profoundly effective mode of action.
Translational Relevance: Confirming Results in Human Brain Organoids:
To bridge the gap between animal models and human relevance, the IBS team extended their investigation to human brain models. Leveraging cutting-edge CRISPR gene editing technology, they created human cortical organoids—miniature, three-dimensional cellular structures derived from pluripotent stem cells that mimic key aspects of human brain development and function—carrying SHANK2 or SHANK3 mutations. As observed in the mouse models, these human organoids exhibited reduced NMDAR activity, validating them as accurate in vitro models for the human condition.
An ASO specifically designed to target the human SLC6A20 gene was then applied to these mutated organoids. Remarkably, this human-specific ASO successfully restored NMDAR function to levels closely approximating those found in healthy control organoids. This critical validation step in a human-derived system significantly bolsters the translational potential of the findings.
Director Eunjoon Kim emphasized the strategic advantage of this approach, stating, "Unlike gene re-expression strategies, SLC6A20 inhibition works by modulating endogenous signaling pathways and may offer a more practical therapeutic route. The fact that the effect was reproduced not only in mice but also in human cortical organoids suggests that this approach may represent a promising therapeutic strategy for neurodevelopmental disorders characterized by NMDA receptor hypofunction." This statement highlights the elegance of working within the brain’s existing regulatory systems, potentially leading to more nuanced and safer interventions compared to attempts at directly replacing or overexpressing genes.
Durability and Safety Profile:
Another crucial aspect of the study concerned the longevity and safety of the treatment. The researchers reported that a single administration of the Slc6a20a ASO remained effective for an impressive duration of at least eight weeks. Furthermore, throughout this period, no detectable adverse effects were observed in the treated mouse models, a critical indicator for future therapeutic development. The sustained effect from a single dose suggests a potentially less burdensome treatment regimen for patients, reducing the frequency of administration and improving compliance.
Broader Implications and Future Horizons
While the immediate focus of this groundbreaking study was autism spectrum disorder, the implications of targeting SLC6A20 extend far beyond. Given that reduced NMDAR activity is a common underlying pathology in a range of neuropsychiatric and neurodevelopmental conditions, including schizophrenia and certain forms of intellectual disability, this approach could offer a versatile platform for developing treatments for a much broader patient population. Schizophrenia, for instance, affects approximately 0.32% of the global population, and intellectual disability impacts 1-3% worldwide, underscoring the vast potential societal benefit of a treatment targeting NMDAR hypofunction.
Official Responses and Expert Commentary (Inferred):
The scientific community is likely to greet these findings with significant enthusiasm and cautious optimism. Experts in neurodevelopmental disorders would commend the IBS team for identifying a highly specific and functionally impactful therapeutic target. Dr. Kim’s explicit mention of a "practical therapeutic route" resonates with the ongoing challenges in drug discovery for complex brain disorders, where broad-acting compounds often fail due to systemic side effects. Patient advocacy groups would likely express a renewed sense of hope, emphasizing the potential for improved quality of life for individuals and families affected by ASD and related conditions, particularly given the demonstrated efficacy in adult models, which addresses a significant unmet need. Regulatory bodies and pharmaceutical companies would undoubtedly take keen interest, recognizing the potential for a new class of ASO-based therapies targeting SLC6A20 to enter preclinical development.
Translational Challenges and Next Steps:
Despite the remarkable promise, the journey from these initial findings to a widely available clinical treatment is long and complex. The next critical steps will involve:
- Further Preclinical Optimization: Refining ASO chemistry and delivery methods to ensure optimal brain penetration and sustained effect in larger animal models.
- Comprehensive Toxicology Studies: Rigorous safety assessments in multiple animal species to identify any potential off-target effects or long-term toxicities.
- Human Clinical Trials: If preclinical studies are successful, the ultimate test will be human clinical trials, starting with Phase 1 studies to assess safety and tolerability in healthy volunteers, followed by Phase 2 and 3 trials to evaluate efficacy in patient populations.
- Patient Stratification: Identifying specific biomarkers or genetic profiles that predict which individuals with NMDAR hypofunction-related disorders would most benefit from SLC6A20 inhibition.
The development of ASO therapies, while promising, also presents challenges related to manufacturing complexity and cost. However, the success of existing ASO drugs, such as nusinersen for spinal muscular atrophy, demonstrates the viability of this therapeutic modality in severe neurological conditions.
In conclusion, the research from the IBS Center for Synaptic Brain Dysfunctions represents a monumental step forward in understanding and potentially treating neurodevelopmental disorders characterized by NMDA receptor hypofunction. By precisely targeting Slc6a20a/SLC6A20, Director Eunjoon Kim and her team have not only identified a promising new therapeutic target but also laid a robust foundation for the development of highly specific and effective treatments, offering a beacon of hope for millions affected by autism spectrum disorder and related conditions worldwide. The implications of this work could reverberate across neurology, shaping future therapeutic strategies for some of the most challenging conditions confronting modern medicine.
